Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials

BACKGROUND: Funding and resources for low prevalent neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) are limited, and optimising their use is vital for efficient drug development. In this study, we review the design assumptions for pivotal ALS clinical trials with time-to-even...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Neurol Neurosurg Psychiatry
Asıl Yazarlar: van Eijk, Ruben P A, Nikolakopoulos, Stavros, Roes, Kit C B, Middelkoop, Bas M, Ferguson, Toby A, Shaw, Pamela J, Leigh, P Nigel, Al-Chalabi, Ammar, Eijkemans, Marinus J C, van den Berg, Leonard H
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2019
Konular:
Neuromuscular
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6902062/
https://ncbi.nlm.nih.gov/pubmed/31292200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jnnp-2019-320998
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller